Resonant plans to raise $9.2 million in public offering
Resonant, a late stage Goleta development company designing small smartphone technology, plans to raise $9.2 million in a public offering. Documents filed with the Securities and Exchange Commission Sept. 9 said the company plans to offer about 2.4 million shares for $4.25 per share. The company expects to complete the offering by Sept. 14. Resonant Read More →
Greed drives skyrocketing cost of drugs in the U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA approves Amgen’s Blincyto
The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →
Amgen acquires German drug
Story updated at 11 a.m.: Thousand Oaks-based biotech giant Amgen acquired global development rights to a multiple myeloma drug from a German company Sept. 1. Amgen said in a news release it acquired commercial and development rights to BI 836909, which is currently being developed by German company Boehringer Ingelheim. It will work with Boehringer Read More →
Semtech Q2 revenues soar
Semtech revenues increased along with profits and earnings per share during the second quarter of fiscal year 2017 the company announced Aug. 31. Semtech, a Camarillo-based manufacturer of semi-conductors for the smartphone industry, released quarterly earnings results Aug. 31. Revenues increased 8 percent from $125.7 million during the same quarter last year to $135.9 million Read More →
FDA approves biosimilar of Amgen’s Enbrel
The U.S. Food and Drug Administration formally approved a competing biosimilar of Amgen’s top-selling drug Enbrel on Aug. 30. Made by Switzerland-based Novartis, Erelzi mimics the effects of Enbrel. Enbrel, which was first approved in 1998, is approved to treat rheumatoid arthritis and other conditions by decreasing the amount of a protein produced by the Read More →
Net income down but Montecitio Bank & Trust’s loans and deposits grow
Santa Barbara-based Montecito Bank & Trust reported net income of $7.2 million in the second quarter, down $800,000 from the same period last year. The bank reported 13.6 percent year-over-year loan growth, ending the quarter at $752 million. Total deposit growth was up 3.3 percent from the second quarter of 2015 while total assets grew Read More →
